---
layout: post
title: "Determination of Regulatory Review Period for Purposes of Patent Extension; Symplicity Spyral Renal Denervation System"
date: 2026-02-04 21:07:43 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2026-01574
original_published: 2026-01-27 00:00:00 +0000
significance: 8.00
---

# Determination of Regulatory Review Period for Purposes of Patent Extension; Symplicity Spyral Renal Denervation System

**Published:** February 04, 2026 21:07 UTC
**Source:** Federal Register
**Original Published:** January 27, 2026 00:00 UTC
**Document Number:** 2026-01574

## Summary

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that medical device.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2026/01/27/2026-01574/determination-of-regulatory-review-period-for-purposes-of-patent-extension-symplicity-spyral-renal)
- API: https://www.federalregister.gov/api/v1/documents/2026-01574

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
